Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Argus Health
Chinese Patent Office
Medtronic
Teva
Cantor Fitzgerald
Colorcon
Citi
Mallinckrodt

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021742

« Back to Dashboard

NDA 021742 describes BYSTOLIC, which is a drug marketed by Allergan Sales Llc and is included in one NDA. It is available from six suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the BYSTOLIC profile page.

The generic ingredient in BYSTOLIC is nebivolol hydrochloride. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the nebivolol hydrochloride profile page.
Summary for 021742
Tradename:BYSTOLIC
Applicant:Allergan Sales Llc
Ingredient:nebivolol hydrochloride
Patents:1
Pharmacology for NDA: 021742
Mechanism of ActionAdrenergic beta-Antagonists
Medical Subject Heading (MeSH) Categories for 021742
Suppliers and Packaging for NDA: 021742
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742 NDA Allergan USA, Inc. 0456-1402 N 0456-1402-90
BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742 NDA Allergan USA, Inc. 0456-1402 N 0456-1402-01

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2.5MG BASE
Approval Date:Dec 17, 2007TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 17, 2021Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF HYPERTENSION

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Dec 17, 2007TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 17, 2021Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF HYPERTENSION

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Dec 17, 2007TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 17, 2021Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF HYPERTENSION

Expired US Patents for NDA 021742

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742-004 Dec 17, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742-005 Oct 8, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742-002 Dec 17, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742-003 Dec 17, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
Covington
McKesson
Queensland Health
Healthtrust
Julphar
Cerilliant
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.